ArticleInvestigational new drugs2025
BRPF1 inhibitor GSK6853 inhibits NSCLC cell proliferation via the JAK2/STAT3/CCNA2 axis to induce cell cycle arrest.
Article in Investigational new drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide, and current therapies offer limited efficacy for many patients. GSK6853, a selective inhibitor of the BRPF1, has shown promising anticancer activity in preclinical studies. However, its therapeutic potential and underlying molecular mechanisms in NSCLC remain uncharacterized. We evaluated the antiproliferative effects of GSK6853 on A549 and H1975 using CCK-8 and colony formation assays. Cell cycle distribution was analyzed by flow cytometry. Annexin V/PI method was performed to detect the rate of apoptosis. Transcriptomic changes induced by GSK6853 were assessed via RNA sequencing, followed by functional enrichment analysis and protein-protein interaction (PPI) network construction. Hub gene identification and pathway predictions were performed using bioinformatics tools. Western blotting was used to validate key protein expression changes. GSK6853 significantly inhibited the proliferation of A549 and H1975 cells in a dose-dependent manner and induced G0/G1 cell cycle arrest and apoptosis. RNA-seq analysis revealed that GSK6853 downregulated genes involved in DNA replication, homologous recombination, and base excision repair pathways. CCNA2 (Cyclin A2) emerged as a central hub gene among the downregulated targets. Western blotting confirmed that GSK6853 suppressed CCNA2 expression via inhibition of the JAK2/STAT3 signaling pathway. Clinical database analysis further showed that CCNA2 is highly expressed in LUAD tissues and its overexpression correlates with poor overall and disease-free survival. Our findings demonstrate that GSK6853 exerts potent antiproliferative effects in NSCLC by disrupting JAK2/STAT3 signaling pathway and suppressing CCNA2-mediated cell cycle progression, and further stimulates apoptosis. These results highlight GSK6853 as a promising therapeutic candidate for lung adenocarcinoma and support further preclinical and clinical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.